EMEA Office
Louizalaan 489
1050 Brussels
Belgium
Assess your organization against the FDA’s March 2026 draft guidance for responding to Form 483 observations after a drug CGMP inspection. Use this practical readiness checklist to identify gaps, reduce inspection risk, and strengthen your response process.
This FDA readiness scorecard helps you assess whether your QMS is prepared to respond to Form 483 observations in line with the FDA’s March 2026 draft guidance. In less than 20 minutes, you will uncover gaps across inspection readiness, investigations, CAPAs, data integrity, and quality culture.
This FDA readiness scorecard includes:
EMEA Office
Louizalaan 489
1050 Brussels
Belgium
US Office
Scilife Inc.
228 E 45th St. RM 9E
New York, NY 10017
PRODUCT
RESOURCES
COMPANY
Contact Us
EMEA Office
Louizalaan 489
1050 Brussels
Belgium
US Office
Scilife Inc.
228 E 45th St. RM 9E
New York, NY 10017
Copyright 2026 Scilife N.V. All rights reserved.